Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study

Mild cognitive impairment in Parkinson's disease is associated with progression to dementia (Parkinson's disease dementia) in a majority of patients. Determining structural imaging biomarkers associated with prodromal Parkinson's disease dementia may allow for the earlier identificati...

Full description

Saved in:
Bibliographic Details
Published inBrain (London, England : 1878) Vol. 138; no. 10; pp. 2974 - 2986
Main Authors Mak, Elijah, Su, Li, Williams, Guy B., Firbank, Michael J., Lawson, Rachael A., Yarnall, Alison J., Duncan, Gordon W., Owen, Adrian M., Khoo, Tien K., Brooks, David J., Rowe, James B., Barker, Roger A., Burn, David J., O’Brien, John T.
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.10.2015
Subjects
Online AccessGet full text
ISSN0006-8950
1460-2156
1460-2156
DOI10.1093/brain/awv211

Cover

Loading…
Abstract Mild cognitive impairment in Parkinson's disease is associated with progression to dementia (Parkinson's disease dementia) in a majority of patients. Determining structural imaging biomarkers associated with prodromal Parkinson's disease dementia may allow for the earlier identification of those at risk, and allow for targeted disease modifying therapies. One hundred and five non-demented subjects with newly diagnosed idiopathic Parkinson's disease and 37 healthy matched controls had serial 3 T structural magnetic resonance imaging scans with clinical and neuropsychological assessments at baseline, which were repeated after 18 months. The Movement Disorder Society Task Force criteria were used to classify the Parkinson's disease subjects into Parkinson's disease with mild cognitive impairment (n = 39) and Parkinson's disease with no cognitive impairment (n = 66). Freesurfer image processing software was used to measure cortical thickness and subcortical volumes at baseline and follow-up. We compared regional percentage change of cortical thinning and subcortical atrophy over 18 months. At baseline, cases with Parkinson's disease with mild cognitive impairment demonstrated widespread cortical thinning relative to controls and atrophy of the nucleus accumbens compared to both controls and subjects with Parkinson's disease with no cognitive impairment. Regional cortical thickness at baseline was correlated with global cognition in the combined Parkinson's disease cohort. Over 18 months, patients with Parkinson's disease with mild cognitive impairment demonstrated more severe cortical thinning in frontal and temporo-parietal cortices, including hippocampal atrophy, relative to those with Parkinson's disease and no cognitive impairment and healthy controls, whereas subjects with Parkinson's disease and no cognitive impairment showed more severe frontal cortical thinning compared to healthy controls. At baseline, Parkinson's disease with no cognitive impairment converters showed bilateral temporal cortex thinning relative to the Parkinson's disease with no cognitive impairment stable subjects. Although loss of both cortical and subcortical volume occurs in non-demented Parkinson's disease, our longitudinal analyses revealed that Parkinson's disease with mild cognitive impairment shows more extensive atrophy and greater percentage of cortical thinning compared to Parkinson's disease with no cognitive impairment. In particular, an extension of cortical thinning in the temporo-parietal regions in addition to frontal atrophy could be a biomarker in therapeutic studies of mild cognitive impairment in Parkinson's disease for progression towards dementia.
AbstractList Mild cognitive impairment in Parkinson’s disease (PDMCI) is associated with progression to dementia in a majority of patients. Mak et al. reveal accelerated cortical thinning in patients with PDMCI compared to non-cognitively impaired patients and healthy controls. Patterns of cortical thinning may constitute biomarkers for increased dementia risk. Mild cognitive impairment in Parkinson’s disease (PDMCI) is associated with progression to dementia in a majority of patients. Mak et al. reveal accelerated cortical thinning in patients with PDMCI compared to non-cognitively impaired patients and healthy controls. Patterns of cortical thinning may constitute biomarkers for increased dementia risk. Mild cognitive impairment in Parkinson’s disease is associated with progression to dementia (Parkinson’s disease dementia) in a majority of patients. Determining structural imaging biomarkers associated with prodromal Parkinson’s disease dementia may allow for the earlier identification of those at risk, and allow for targeted disease modifying therapies. One hundred and five non-demented subjects with newly diagnosed idiopathic Parkinson’s disease and 37 healthy matched controls had serial 3 T structural magnetic resonance imaging scans with clinical and neuropsychological assessments at baseline, which were repeated after 18 months. The Movement Disorder Society Task Force criteria were used to classify the Parkinson’s disease subjects into Parkinson’s disease with mild cognitive impairment ( n = 39) and Parkinson’s disease with no cognitive impairment ( n = 66). Freesurfer image processing software was used to measure cortical thickness and subcortical volumes at baseline and follow-up. We compared regional percentage change of cortical thinning and subcortical atrophy over 18 months. At baseline, cases with Parkinson’s disease with mild cognitive impairment demonstrated widespread cortical thinning relative to controls and atrophy of the nucleus accumbens compared to both controls and subjects with Parkinson’s disease with no cognitive impairment. Regional cortical thickness at baseline was correlated with global cognition in the combined Parkinson’s disease cohort. Over 18 months, patients with Parkinson’s disease with mild cognitive impairment demonstrated more severe cortical thinning in frontal and temporo-parietal cortices, including hippocampal atrophy, relative to those with Parkinson’s disease and no cognitive impairment and healthy controls, whereas subjects with Parkinson’s disease and no cognitive impairment showed more severe frontal cortical thinning compared to healthy controls. At baseline, Parkinson’s disease with no cognitive impairment converters showed bilateral temporal cortex thinning relative to the Parkinson’s disease with no cognitive impairment stable subjects. Although loss of both cortical and subcortical volume occurs in non-demented Parkinson’s disease, our longitudinal analyses revealed that Parkinson’s disease with mild cognitive impairment shows more extensive atrophy and greater percentage of cortical thinning compared to Parkinson’s disease with no cognitive impairment. In particular, an extension of cortical thinning in the temporo-parietal regions in addition to frontal atrophy could be a biomarker in therapeutic studies of mild cognitive impairment in Parkinson’s disease for progression towards dementia.
Mild cognitive impairment in Parkinson's disease is associated with progression to dementia (Parkinson's disease dementia) in a majority of patients. Determining structural imaging biomarkers associated with prodromal Parkinson's disease dementia may allow for the earlier identification of those at risk, and allow for targeted disease modifying therapies. One hundred and five non-demented subjects with newly diagnosed idiopathic Parkinson's disease and 37 healthy matched controls had serial 3 T structural magnetic resonance imaging scans with clinical and neuropsychological assessments at baseline, which were repeated after 18 months. The Movement Disorder Society Task Force criteria were used to classify the Parkinson's disease subjects into Parkinson's disease with mild cognitive impairment (n = 39) and Parkinson's disease with no cognitive impairment (n = 66). Freesurfer image processing software was used to measure cortical thickness and subcortical volumes at baseline and follow-up. We compared regional percentage change of cortical thinning and subcortical atrophy over 18 months. At baseline, cases with Parkinson's disease with mild cognitive impairment demonstrated widespread cortical thinning relative to controls and atrophy of the nucleus accumbens compared to both controls and subjects with Parkinson's disease with no cognitive impairment. Regional cortical thickness at baseline was correlated with global cognition in the combined Parkinson's disease cohort. Over 18 months, patients with Parkinson's disease with mild cognitive impairment demonstrated more severe cortical thinning in frontal and temporo-parietal cortices, including hippocampal atrophy, relative to those with Parkinson's disease and no cognitive impairment and healthy controls, whereas subjects with Parkinson's disease and no cognitive impairment showed more severe frontal cortical thinning compared to healthy controls. At baseline, Parkinson's disease with no cognitive impairment converters showed bilateral temporal cortex thinning relative to the Parkinson's disease with no cognitive impairment stable subjects. Although loss of both cortical and subcortical volume occurs in non-demented Parkinson's disease, our longitudinal analyses revealed that Parkinson's disease with mild cognitive impairment shows more extensive atrophy and greater percentage of cortical thinning compared to Parkinson's disease with no cognitive impairment. In particular, an extension of cortical thinning in the temporo-parietal regions in addition to frontal atrophy could be a biomarker in therapeutic studies of mild cognitive impairment in Parkinson's disease for progression towards dementia.
Author Lawson, Rachael A.
Khoo, Tien K.
Burn, David J.
Rowe, James B.
Mak, Elijah
Brooks, David J.
Owen, Adrian M.
O’Brien, John T.
Duncan, Gordon W.
Su, Li
Barker, Roger A.
Yarnall, Alison J.
Firbank, Michael J.
Williams, Guy B.
Author_xml – sequence: 1
  givenname: Elijah
  surname: Mak
  fullname: Mak, Elijah
– sequence: 2
  givenname: Li
  surname: Su
  fullname: Su, Li
– sequence: 3
  givenname: Guy B.
  surname: Williams
  fullname: Williams, Guy B.
– sequence: 4
  givenname: Michael J.
  surname: Firbank
  fullname: Firbank, Michael J.
– sequence: 5
  givenname: Rachael A.
  surname: Lawson
  fullname: Lawson, Rachael A.
– sequence: 6
  givenname: Alison J.
  surname: Yarnall
  fullname: Yarnall, Alison J.
– sequence: 7
  givenname: Gordon W.
  surname: Duncan
  fullname: Duncan, Gordon W.
– sequence: 8
  givenname: Adrian M.
  surname: Owen
  fullname: Owen, Adrian M.
– sequence: 9
  givenname: Tien K.
  surname: Khoo
  fullname: Khoo, Tien K.
– sequence: 10
  givenname: David J.
  surname: Brooks
  fullname: Brooks, David J.
– sequence: 11
  givenname: James B.
  surname: Rowe
  fullname: Rowe, James B.
– sequence: 12
  givenname: Roger A.
  surname: Barker
  fullname: Barker, Roger A.
– sequence: 13
  givenname: David J.
  surname: Burn
  fullname: Burn, David J.
– sequence: 14
  givenname: John T.
  surname: O’Brien
  fullname: O’Brien, John T.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26173861$$D View this record in MEDLINE/PubMed
oai:portal.research.lu.se:publications/aae6f9b1-2476-46a7-80c4-943974842870$$DView record from Swedish Publication Index
BookMark eNptkstuEzEUhi1URC-wY428ZMFQ38aeYYFUQoFIkegC1pZjn5kYHDvYk0bZ8Rq8Hk-CaUpFEStL9ne-_xz5nKKjmCIg9JSSl5T0_HyZjY_nZnfNKH2ATqiQpGG0lUfohBAim65vyTE6LeULIVRwJh-hYyap4p2kJ2h8YwoEHwGb6HBIcfTT1vloAh4z7PHaTBNkbFcmjlCwjzjCLuyx82aMqYDDVyZ_9bGk-PP7j1LvC1TjKzyfzWeLy-bqLS5VuH-MHg4mFHhye56hz-8uP80-NIuP7-ezi0VjhRJT03ZtzwclJSNMMG47IEsLrRlASmWdVJw7MMo5GPolDK3oXe86Jl3PgRPJ-BkyB2_ZwWa71Jvs1ybvdTJeb1KeTNAZaovZrnTY6gK6UsFbM_kUizYGZDVTzYSSWkijdEes0L3gvRKdYJ0iNeP1IaOWrsFZiFOu3ntR916iX-kxXVefokKpKnh-K8jp2xbKpNe-WAjBREjboqmiHalxpKvos7-z7kL-_GAFXhwAm1MpGYY7hBL9e0H0zYLow4JUnP2DWz_dDF879eH_Rb8AZsvExw
CitedBy_id crossref_primary_10_1002_mdc3_12391
crossref_primary_10_1016_j_parkreldis_2024_107077
crossref_primary_10_1016_j_nicl_2017_11_009
crossref_primary_10_1016_j_brainres_2020_146847
crossref_primary_10_1177_0004867419885165
crossref_primary_10_1007_s11682_017_9751_6
crossref_primary_10_1002_brb3_3454
crossref_primary_10_1002_mds_30081
crossref_primary_10_1155_2016_3217960
crossref_primary_10_1007_s10548_018_0675_2
crossref_primary_10_1016_j_jns_2019_01_020
crossref_primary_10_3390_metabo11030145
crossref_primary_10_1016_j_neuropsychologia_2020_107593
crossref_primary_10_1002_mds_27106
crossref_primary_10_1038_s42003_024_06648_x
crossref_primary_10_1111_ene_70022
crossref_primary_10_1111_pcn_12919
crossref_primary_10_1007_s11571_022_09868_1
crossref_primary_10_1007_s11682_022_00714_w
crossref_primary_10_1016_j_neurom_2022_01_013
crossref_primary_10_1016_j_parkreldis_2016_06_019
crossref_primary_10_1002_mds_27902
crossref_primary_10_1007_s00429_018_1677_2
crossref_primary_10_1038_npjparkd_2016_18
crossref_primary_10_3389_fneur_2019_00195
crossref_primary_10_1007_s00415_015_7929_7
crossref_primary_10_1016_j_cortex_2017_08_030
crossref_primary_10_1016_j_ibneur_2024_03_001
crossref_primary_10_1038_s41598_018_29017_1
crossref_primary_10_1038_s41531_022_00372_1
crossref_primary_10_3389_fnagi_2022_788846
crossref_primary_10_1002_jnr_24863
crossref_primary_10_3233_JPD_230455
crossref_primary_10_1016_j_nicl_2023_103523
crossref_primary_10_1111_ejn_15640
crossref_primary_10_1038_s41582_023_00905_z
crossref_primary_10_1016_j_neuroimage_2021_117756
crossref_primary_10_3233_JAD_160597
crossref_primary_10_3233_JPD_181471
crossref_primary_10_1136_bmjopen_2019_034110
crossref_primary_10_1007_s11910_019_0964_5
crossref_primary_10_1007_s00221_017_4916_5
crossref_primary_10_1038_nrneurol_2017_27
crossref_primary_10_1016_j_bpsc_2021_10_011
crossref_primary_10_3233_JPD_160824
crossref_primary_10_1038_s41467_024_49949_9
crossref_primary_10_1002_hbm_24884
crossref_primary_10_1007_s00415_020_09863_8
crossref_primary_10_1002_hbm_25211
crossref_primary_10_3390_brainsci11010055
crossref_primary_10_1097_WNR_0000000000001448
crossref_primary_10_3390_medicina60010115
crossref_primary_10_1007_s00415_023_11947_0
crossref_primary_10_1002_nbm_3900
crossref_primary_10_1016_j_nicl_2020_102374
crossref_primary_10_1038_s41531_022_00416_6
crossref_primary_10_1002_mds_27364
crossref_primary_10_1016_j_jns_2020_117177
crossref_primary_10_1002_mds_29026
crossref_primary_10_1016_j_pscychresns_2023_111719
crossref_primary_10_1371_journal_pone_0222002
crossref_primary_10_1093_brain_awad265
crossref_primary_10_1136_jnnp_2017_316075
crossref_primary_10_1002_hbm_24593
crossref_primary_10_1186_s41983_023_00662_2
crossref_primary_10_1016_j_pscychresns_2018_03_004
crossref_primary_10_1002_hbm_24631
crossref_primary_10_1016_j_parkreldis_2019_09_031
crossref_primary_10_1016_j_neurobiolaging_2022_10_001
crossref_primary_10_1111_cns_13188
crossref_primary_10_1007_s11910_019_1006_z
crossref_primary_10_1007_s00330_018_5342_1
crossref_primary_10_1148_radiol_2021210420
crossref_primary_10_1007_s11910_018_0894_7
crossref_primary_10_3389_fnins_2023_1278817
crossref_primary_10_1093_brain_awy211
crossref_primary_10_1016_j_parkreldis_2023_105766
crossref_primary_10_1097_RLU_0000000000005211
crossref_primary_10_1016_j_parkreldis_2017_11_003
crossref_primary_10_1002_hbm_23499
crossref_primary_10_1016_j_clinph_2019_04_314
crossref_primary_10_1002_mds_27115
crossref_primary_10_1002_mds_26662
crossref_primary_10_3389_fnagi_2024_1459652
crossref_primary_10_1002_mds_27355
crossref_primary_10_3389_fnagi_2020_00199
crossref_primary_10_1007_s10072_023_07040_z
crossref_primary_10_1007_s11682_020_00428_x
crossref_primary_10_1016_j_bandl_2017_01_005
crossref_primary_10_1002_gps_6074
crossref_primary_10_1212_WNL_0000000000010347
crossref_primary_10_21303_2504_5679_2018_00794
crossref_primary_10_3389_fnana_2024_1362165
crossref_primary_10_1016_j_parkreldis_2020_11_010
crossref_primary_10_1111_cns_14728
crossref_primary_10_1007_s11682_018_9922_0
crossref_primary_10_1097_HRP_0000000000000283
crossref_primary_10_1186_s12883_020_01874_2
crossref_primary_10_1016_j_jpsychires_2018_04_016
crossref_primary_10_1007_s11065_021_09502_7
crossref_primary_10_1016_j_cortex_2017_05_011
crossref_primary_10_1016_j_nicl_2021_102745
crossref_primary_10_2147_JPRLS_S263041
crossref_primary_10_1016_j_jns_2016_12_030
crossref_primary_10_1016_j_pscychresns_2016_07_006
crossref_primary_10_1111_cns_14680
crossref_primary_10_1155_2021_5579888
crossref_primary_10_1002_mds_27386
crossref_primary_10_1148_radiol_232454
crossref_primary_10_1016_j_neurobiolaging_2021_08_020
crossref_primary_10_1016_j_parkreldis_2016_07_019
crossref_primary_10_1093_brain_awx310
crossref_primary_10_1007_s40120_021_00318_4
crossref_primary_10_1007_s00330_021_08086_3
crossref_primary_10_1111_ene_13205
crossref_primary_10_1172_JCI157074
crossref_primary_10_3390_healthcare6020035
crossref_primary_10_3389_fpsyt_2016_00089
crossref_primary_10_1155_2022_8493729
crossref_primary_10_1371_journal_pone_0187939
crossref_primary_10_1111_acps_13065
crossref_primary_10_1016_j_neuropsychologia_2018_03_011
crossref_primary_10_3389_fnins_2020_567222
crossref_primary_10_1097_HJH_0000000000002505
crossref_primary_10_1002_mds_28228
crossref_primary_10_1038_s41380_019_0608_9
crossref_primary_10_1371_journal_pone_0236728
crossref_primary_10_3389_fnhum_2018_00469
crossref_primary_10_1093_texcom_tgac044
crossref_primary_10_1002_mds_26968
crossref_primary_10_1007_s11682_024_00931_5
crossref_primary_10_1093_braincomms_fcz006
crossref_primary_10_1097_WCO_0000000000000498
crossref_primary_10_1212_WNL_0000000000007968
crossref_primary_10_1016_j_nbd_2018_11_001
crossref_primary_10_18632_aging_202368
crossref_primary_10_3233_JPD_191748
crossref_primary_10_30629_2658_7947_2022_27_4_37_43
crossref_primary_10_1002_hbm_25650
crossref_primary_10_3389_fcogn_2024_1369538
crossref_primary_10_1016_j_parkreldis_2024_107134
crossref_primary_10_1016_j_cortex_2018_11_021
crossref_primary_10_1016_j_cortex_2017_07_003
crossref_primary_10_1016_j_cortex_2022_03_009
crossref_primary_10_1016_j_jns_2017_04_010
crossref_primary_10_1016_j_nicl_2016_12_025
crossref_primary_10_1002_hbm_23628
crossref_primary_10_1007_s11011_023_01180_z
crossref_primary_10_1007_s42600_020_00072_w
crossref_primary_10_1016_j_parkreldis_2020_04_009
crossref_primary_10_1093_brain_awaa234
crossref_primary_10_1097_WCO_0000000000000521
crossref_primary_10_2174_1570159X21666230801140648
crossref_primary_10_3389_fnagi_2018_00089
crossref_primary_10_3389_fneur_2020_00047
crossref_primary_10_1001_jamaneurol_2021_1312
crossref_primary_10_3389_fnagi_2022_781480
crossref_primary_10_1002_brb3_573
crossref_primary_10_3389_fnagi_2019_00191
crossref_primary_10_1007_s11682_021_00543_3
crossref_primary_10_1093_arclin_acx091
crossref_primary_10_3389_fnagi_2021_745438
crossref_primary_10_3390_ctn7010008
crossref_primary_10_1016_j_parkreldis_2019_03_027
crossref_primary_10_1186_s41155_023_00259_x
crossref_primary_10_1093_braincomms_fcab269
crossref_primary_10_1016_j_neubiorev_2017_07_001
crossref_primary_10_1148_radiol_2021203383
crossref_primary_10_1007_s11910_018_0907_6
crossref_primary_10_1002_acn3_50927
crossref_primary_10_1093_brain_awae303
crossref_primary_10_1093_braincomms_fcaa051
crossref_primary_10_1002_hbm_23610
crossref_primary_10_1016_j_bbr_2019_112039
crossref_primary_10_3233_JPD_150652
crossref_primary_10_1002_mds_27951
crossref_primary_10_1002_mds_28886
crossref_primary_10_1007_s00415_018_8873_0
crossref_primary_10_1016_j_bbr_2025_115484
crossref_primary_10_1016_j_parkreldis_2024_106030
Cites_doi 10.1212/WNL.0000000000000483
10.1177/0891988705277540
10.1016/j.neurobiolaging.2014.12.038
10.1016/j.neuroimage.2006.07.036
10.1136/jnnp-2012-304126
10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z
10.1016/0022-3956(75)90026-6
10.1002/hbm.21378
10.1093/brain/awp245
10.1212/WNL.49.6.1570
10.1093/brain/awu201
10.1212/WNL.0b013e3181fc29c9
10.1002/mds.23429
10.1212/01.wnl.0000191154.78131.f6
10.1006/nimg.1998.0396
10.1007/s00259-012-2198-5
10.1001/archneurol.2011.725
10.1016/j.neurobiolaging.2008.08.008
10.1016/S1474-4422(06)70600-7
10.1093/brain/awf080
10.1136/jnnp-2013-305062
10.1016/j.neurobiolaging.2009.10.012
10.1371/journal.pone.0054980
10.1136/jnnp.2006.093849
10.1093/brain/awh088
10.1001/archneur.60.3.387
10.1007/s00702-013-0988-y
10.1016/j.neuroimage.2012.02.084
10.1002/mds.22341
10.1002/mds.25157
10.1016/j.neuroimage.2011.02.076
10.1093/brain/awu036
10.1212/WNL.0000000000000066
10.1016/j.neuroimage.2010.07.020
10.1016/j.neurobiolaging.2008.07.009
10.1002/mds.25240
10.3233/JPD-120151
10.1093/brain/awm111
10.1002/mds.25541
10.1159/000048651
10.1212/WNL.0b013e31827deb74
10.1038/nrn1178
10.1016/0892-0362(96)00027-X
10.1002/ana.10078
10.1212/WNL.0b013e3181d55f61
10.1016/j.parkreldis.2014.10.014
10.1002/mds.22867
10.1073/pnas.200033797
10.1016/0022-3956(82)90033-4
10.1016/j.neurobiolaging.2010.09.004
10.1016/j.neulet.2007.04.049
10.1002/mds.23453
10.1016/j.neuroimage.2010.12.043
10.1159/000341998
10.1126/scitranslmed.3000976
10.1212/01.wnl.0000247740.47667.03
10.1002/mds.24893
10.3174/ajnr.A4055
10.1002/mds.25812
10.1136/jnnp-2011-300828
10.1002/mds.23477
10.1093/cercor/bhh032
10.1016/j.neuroimage.2012.06.012
10.1002/mds.20652
10.1001/jamaneurol.2013.2110
10.1016/j.parkreldis.2008.03.005
10.1176/appi.ajp.2008.08081201
10.1016/j.neurobiolaging.2010.09.027
10.1016/j.parkreldis.2014.03.009
10.1002/hbm.21245
ContentType Journal Article
Copyright The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain.
The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. 2015
Copyright_xml – notice: The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain.
– notice: The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. 2015
CorporateAuthor Strategiska forskningsområden (SFO)
Strategic research areas (SRA)
MultiPark: Multidisciplinary research focused on Parkinson's disease
Profile areas and other strong research environments
Lunds universitet
Lund University
Profilområden och andra starka forskningsmiljöer
CorporateAuthor_xml – name: Strategiska forskningsområden (SFO)
– name: Profilområden och andra starka forskningsmiljöer
– name: Lund University
– name: Profile areas and other strong research environments
– name: Strategic research areas (SRA)
– name: MultiPark: Multidisciplinary research focused on Parkinson's disease
– name: Lunds universitet
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
DOI 10.1093/brain/awv211
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SWEPUB Lunds universitet full text
SwePub Articles
SWEPUB Freely available online
SWEPUB Lunds universitet
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2156
EndPage 2986
ExternalDocumentID oai_portal_research_lu_se_publications_aae6f9b1_2476_46a7_80c4_943974842870
PMC4671477
26173861
10_1093_brain_awv211
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Parkinson's UK
  grantid: J-0802
– fundername: Parkinson's UK
  grantid: G-1507
– fundername: Medical Research Council
  grantid: MC_U105597119
– fundername: Medical Research Council
  grantid: MC_U120036861
– fundername: Wellcome Trust
  grantid: 093875
– fundername: Wellcome Trust
  grantid: 103838
– fundername: Medical Research Council
  grantid: G1100810
GroupedDBID ---
-E4
-~X
.2P
.55
.GJ
.I3
.XZ
.ZR
0R~
1CY
1TH
23N
2WC
354
3O-
4.4
41~
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6PF
70D
AABZA
AACZT
AAGKA
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
AAWDT
AAWTL
AAYJJ
AAYXX
ABDFA
ABDPE
ABEJV
ABEUO
ABGNP
ABIME
ABIVO
ABIXL
ABJNI
ABKDP
ABLJU
ABMNT
ABNGD
ABNHQ
ABNKS
ABPIB
ABPQP
ABPTD
ABQLI
ABQNK
ABSMQ
ABVGC
ABWST
ABXVV
ABXZS
ABZBJ
ABZEO
ACBNA
ACFRR
ACGFS
ACIWK
ACPQN
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFQV
AFFZL
AFGWE
AFIYH
AFOFC
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AI.
AIJHB
AJBYB
AJDVS
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
ANFBD
APIBT
APJGH
APWMN
AQDSO
AQKUS
ARIXL
ASAOO
ASPBG
ATDFG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AYOIW
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BR6
BSWAC
BTRTY
BVRKM
BZKNY
C1A
C45
CAG
CDBKE
CITATION
COF
CS3
CXTWN
CZ4
DAKXR
DFGAJ
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EIHJH
EJD
ELUNK
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MBLQV
MBTAY
MHKGH
ML0
MVM
N4W
N9A
NGC
NLBLG
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OBOKY
OCZFY
ODMLO
OHH
OHT
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RIG
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCN
TCURE
TEORI
TJX
TLC
TMA
TR2
VH1
VVN
W8F
WH7
WOQ
X7H
X7M
XJT
XOL
YAYTL
YKOAZ
YQJ
YSK
YXANX
ZCG
ZGI
ZKB
ZKX
ZXP
~91
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
ID FETCH-LOGICAL-c474t-58593f766202423c8e0bce5afe667cd6733dea7ddef9bef549d9d826d93e30623
ISSN 0006-8950
1460-2156
IngestDate Thu Aug 21 06:31:09 EDT 2025
Thu Aug 21 17:24:29 EDT 2025
Fri Jul 11 06:48:24 EDT 2025
Mon Jul 21 05:58:43 EDT 2025
Tue Jul 01 00:46:07 EDT 2025
Thu Apr 24 23:06:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords neurodegeneration
dementia
Parkinson’s disease
neuroimaging
Language English
License The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c474t-58593f766202423c8e0bce5afe667cd6733dea7ddef9bef549d9d826d93e30623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC4671477
PMID 26173861
PQID 1718074808
PQPubID 23479
PageCount 13
ParticipantIDs swepub_primary_oai_portal_research_lu_se_publications_aae6f9b1_2476_46a7_80c4_943974842870
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4671477
proquest_miscellaneous_1718074808
pubmed_primary_26173861
crossref_primary_10_1093_brain_awv211
crossref_citationtrail_10_1093_brain_awv211
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-10-01
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Brain (London, England : 1878)
PublicationTitleAlternate Brain
PublicationYear 2015
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References 2015100801173447000_138.10.2974.48
2015100801173447000_138.10.2974.49
2015100801173447000_138.10.2974.46
2015100801173447000_138.10.2974.47
2015100801173447000_138.10.2974.44
2015100801173447000_138.10.2974.45
2015100801173447000_138.10.2974.42
2015100801173447000_138.10.2974.43
2015100801173447000_138.10.2974.6
2015100801173447000_138.10.2974.40
2015100801173447000_138.10.2974.7
2015100801173447000_138.10.2974.41
2015100801173447000_138.10.2974.8
2015100801173447000_138.10.2974.9
2015100801173447000_138.10.2974.19
2015100801173447000_138.10.2974.17
2015100801173447000_138.10.2974.18
2015100801173447000_138.10.2974.15
2015100801173447000_138.10.2974.59
2015100801173447000_138.10.2974.13
2015100801173447000_138.10.2974.57
2015100801173447000_138.10.2974.14
2015100801173447000_138.10.2974.58
2015100801173447000_138.10.2974.11
Lawson (2015100801173447000_138.10.2974.36) 2014
2015100801173447000_138.10.2974.55
2015100801173447000_138.10.2974.12
2015100801173447000_138.10.2974.56
2015100801173447000_138.10.2974.53
2015100801173447000_138.10.2974.10
2015100801173447000_138.10.2974.54
2015100801173447000_138.10.2974.51
2015100801173447000_138.10.2974.52
2015100801173447000_138.10.2974.50
2015100801173447000_138.10.2974.2
2015100801173447000_138.10.2974.3
2015100801173447000_138.10.2974.4
2015100801173447000_138.10.2974.5
Hoehn (2015100801173447000_138.10.2974.26) 2001; 57
2015100801173447000_138.10.2974.1
Hwang (2015100801173447000_138.10.2974.28) 2013; 3
2015100801173447000_138.10.2974.29
2015100801173447000_138.10.2974.27
2015100801173447000_138.10.2974.24
2015100801173447000_138.10.2974.68
2015100801173447000_138.10.2974.25
2015100801173447000_138.10.2974.69
2015100801173447000_138.10.2974.22
2015100801173447000_138.10.2974.66
2015100801173447000_138.10.2974.23
2015100801173447000_138.10.2974.67
2015100801173447000_138.10.2974.20
2015100801173447000_138.10.2974.64
2015100801173447000_138.10.2974.21
2015100801173447000_138.10.2974.65
2015100801173447000_138.10.2974.62
2015100801173447000_138.10.2974.63
2015100801173447000_138.10.2974.60
2015100801173447000_138.10.2974.61
Foltynie (2015100801173447000_138.10.2974.16) 2004; 127
2015100801173447000_138.10.2974.39
2015100801173447000_138.10.2974.37
2015100801173447000_138.10.2974.38
2015100801173447000_138.10.2974.35
2015100801173447000_138.10.2974.34
2015100801173447000_138.10.2974.31
2015100801173447000_138.10.2974.32
2015100801173447000_138.10.2974.73
2015100801173447000_138.10.2974.30
Kehagia (2015100801173447000_138.10.2974.33) 2012; 11
2015100801173447000_138.10.2974.71
2015100801173447000_138.10.2974.72
2015100801173447000_138.10.2974.70
References_xml – ident: 2015100801173447000_138.10.2974.50
  doi: 10.1212/WNL.0000000000000483
– ident: 2015100801173447000_138.10.2974.30
  doi: 10.1177/0891988705277540
– ident: 2015100801173447000_138.10.2974.42
  doi: 10.1016/j.neurobiolaging.2014.12.038
– ident: 2015100801173447000_138.10.2974.21
  doi: 10.1016/j.neuroimage.2006.07.036
– ident: 2015100801173447000_138.10.2974.73
  doi: 10.1136/jnnp-2012-304126
– ident: 2015100801173447000_138.10.2974.2
  doi: 10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z
– ident: 2015100801173447000_138.10.2974.15
  doi: 10.1016/0022-3956(75)90026-6
– ident: 2015100801173447000_138.10.2974.49
  doi: 10.1002/hbm.21378
– ident: 2015100801173447000_138.10.2974.69
  doi: 10.1093/brain/awp245
– ident: 2015100801173447000_138.10.2974.8
  doi: 10.1212/WNL.49.6.1570
– volume: 127
  start-page: 550
  year: 2004
  ident: 2015100801173447000_138.10.2974.16
  article-title: The cognitive ability of an incident cohort of Parkinson’s patients in the UK
  publication-title: The CamPaIGN study. Brain
– ident: 2015100801173447000_138.10.2974.46
  doi: 10.1093/brain/awu201
– ident: 2015100801173447000_138.10.2974.10
  doi: 10.1212/WNL.0b013e3181fc29c9
– ident: 2015100801173447000_138.10.2974.65
  doi: 10.1002/mds.23429
– ident: 2015100801173447000_138.10.2974.25
  doi: 10.1212/01.wnl.0000191154.78131.f6
– ident: 2015100801173447000_138.10.2974.14
  doi: 10.1006/nimg.1998.0396
– ident: 2015100801173447000_138.10.2974.19
  doi: 10.1007/s00259-012-2198-5
– ident: 2015100801173447000_138.10.2974.66
  doi: 10.1001/archneurol.2011.725
– ident: 2015100801173447000_138.10.2974.3
  doi: 10.1016/j.neurobiolaging.2008.08.008
– ident: 2015100801173447000_138.10.2974.7
  doi: 10.1016/S1474-4422(06)70600-7
– ident: 2015100801173447000_138.10.2974.27
  doi: 10.1093/brain/awf080
– ident: 2015100801173447000_138.10.2974.38
  doi: 10.1136/jnnp-2013-305062
– ident: 2015100801173447000_138.10.2974.68
  doi: 10.1016/j.neurobiolaging.2009.10.012
– ident: 2015100801173447000_138.10.2974.47
  doi: 10.1371/journal.pone.0054980
– ident: 2015100801173447000_138.10.2974.4
  doi: 10.1136/jnnp.2006.093849
– ident: 2015100801173447000_138.10.2974.6
  doi: 10.1093/brain/awh088
– ident: 2015100801173447000_138.10.2974.1
  doi: 10.1001/archneur.60.3.387
– ident: 2015100801173447000_138.10.2974.45
  doi: 10.1007/s00702-013-0988-y
– ident: 2015100801173447000_138.10.2974.58
  doi: 10.1016/j.neuroimage.2012.02.084
– ident: 2015100801173447000_138.10.2974.20
  doi: 10.1002/mds.22341
– ident: 2015100801173447000_138.10.2974.55
  doi: 10.1002/mds.25157
– ident: 2015100801173447000_138.10.2974.56
  doi: 10.1016/j.neuroimage.2011.02.076
– ident: 2015100801173447000_138.10.2974.22
  doi: 10.1093/brain/awu036
– ident: 2015100801173447000_138.10.2974.71
  doi: 10.1212/WNL.0000000000000066
– ident: 2015100801173447000_138.10.2974.57
  doi: 10.1016/j.neuroimage.2010.07.020
– ident: 2015100801173447000_138.10.2974.59
  doi: 10.1016/j.neurobiolaging.2008.07.009
– ident: 2015100801173447000_138.10.2974.29
  doi: 10.1002/mds.25240
– volume: 3
  start-page: 69
  year: 2013
  ident: 2015100801173447000_138.10.2974.28
  article-title: Mapping cortical atrophy in Parkinson’s disease patients with dementia
  publication-title: J Parkinsons Dis
  doi: 10.3233/JPD-120151
– ident: 2015100801173447000_138.10.2974.70
  doi: 10.1093/brain/awm111
– ident: 2015100801173447000_138.10.2974.23
  doi: 10.1002/mds.25541
– ident: 2015100801173447000_138.10.2974.67
  doi: 10.1159/000048651
– ident: 2015100801173447000_138.10.2974.34
  doi: 10.1212/WNL.0b013e31827deb74
– ident: 2015100801173447000_138.10.2974.62
  doi: 10.1038/nrn1178
– ident: 2015100801173447000_138.10.2974.17
  doi: 10.1016/0892-0362(96)00027-X
– ident: 2015100801173447000_138.10.2974.43
  doi: 10.1002/ana.10078
– ident: 2015100801173447000_138.10.2974.35
  doi: 10.1212/WNL.0b013e3181d55f61
– ident: 2015100801173447000_138.10.2974.18
  doi: 10.1016/j.parkreldis.2014.10.014
– ident: 2015100801173447000_138.10.2974.9
  doi: 10.1002/mds.22867
– ident: 2015100801173447000_138.10.2974.13
  doi: 10.1073/pnas.200033797
– ident: 2015100801173447000_138.10.2974.72
  doi: 10.1016/0022-3956(82)90033-4
– ident: 2015100801173447000_138.10.2974.53
  doi: 10.1016/j.neurobiolaging.2010.09.004
– start-page: 1
  year: 2014
  ident: 2015100801173447000_138.10.2974.36
  article-title: Quality of life and mild cognitive impairment in early parkinson’s disease: does subtype matter?
  publication-title: J Parkinsons Dis
– ident: 2015100801173447000_138.10.2974.39
  doi: 10.1016/j.neulet.2007.04.049
– ident: 2015100801173447000_138.10.2974.64
  doi: 10.1002/mds.23453
– volume: 57
  start-page: S11
  year: 2001
  ident: 2015100801173447000_138.10.2974.26
  article-title: Parkinsonism: onset, progression, and mortality
  publication-title: 1967. Neurology
– ident: 2015100801173447000_138.10.2974.32
  doi: 10.1016/j.neuroimage.2010.12.043
– volume: 11
  start-page: 79
  year: 2012
  ident: 2015100801173447000_138.10.2974.33
  article-title: Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis
  publication-title: Neurodegener Dis
  doi: 10.1159/000341998
– ident: 2015100801173447000_138.10.2974.52
  doi: 10.1126/scitranslmed.3000976
– ident: 2015100801173447000_138.10.2974.12
  doi: 10.1212/01.wnl.0000247740.47667.03
– ident: 2015100801173447000_138.10.2974.40
  doi: 10.1002/mds.24893
– ident: 2015100801173447000_138.10.2974.41
  doi: 10.3174/ajnr.A4055
– ident: 2015100801173447000_138.10.2974.61
  doi: 10.1002/mds.25812
– ident: 2015100801173447000_138.10.2974.44
  doi: 10.1136/jnnp-2011-300828
– ident: 2015100801173447000_138.10.2974.63
  doi: 10.1002/mds.23477
– ident: 2015100801173447000_138.10.2974.60
  doi: 10.1093/cercor/bhh032
– ident: 2015100801173447000_138.10.2974.54
  doi: 10.1016/j.neuroimage.2012.06.012
– ident: 2015100801173447000_138.10.2974.5
  doi: 10.1002/mds.20652
– ident: 2015100801173447000_138.10.2974.48
  doi: 10.1001/jamaneurol.2013.2110
– ident: 2015100801173447000_138.10.2974.31
  doi: 10.1016/j.parkreldis.2008.03.005
– ident: 2015100801173447000_138.10.2974.51
  doi: 10.1176/appi.ajp.2008.08081201
– ident: 2015100801173447000_138.10.2974.11
  doi: 10.1016/j.neurobiolaging.2010.09.027
– ident: 2015100801173447000_138.10.2974.37
  doi: 10.1016/j.parkreldis.2014.03.009
– ident: 2015100801173447000_138.10.2974.24
  doi: 10.1002/hbm.21245
SSID ssj0014326
Score 2.5675864
Snippet Mild cognitive impairment in Parkinson's disease is associated with progression to dementia (Parkinson's disease dementia) in a majority of patients....
Mild cognitive impairment in Parkinson’s disease (PDMCI) is associated with progression to dementia in a majority of patients. Mak et al. reveal accelerated...
SourceID swepub
pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2974
SubjectTerms Adult
Aged
Aged, 80 and over
Brain Mapping
Cognition Disorders - etiology
Female
Gray Matter - pathology
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Neuropsychological Tests
Original
Parkinson Disease - complications
Parkinson Disease - pathology
Retrospective Studies
Severity of Illness Index
Statistics, Nonparametric
Title Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study
URI https://www.ncbi.nlm.nih.gov/pubmed/26173861
https://www.proquest.com/docview/1718074808
https://pubmed.ncbi.nlm.nih.gov/PMC4671477
oai:portal.research.lu.se:publications/aae6f9b1-2476-46a7-80c4-943974842870
Volume 138
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiFeEPeGmxYJniKnjr1er3mjoVcRVIlWqnhZre01DU2dKIlB4Ynf4IP4Eb6E2Uu2NgkI-mJFjuN1fI53Z8YzZxB6IcGrCAqY_YQAGEgURZ4gfuExEaTKXGZUqELhwTu6f0IOT6PTVutHLWupmqfd7OvaupKroAr7AFdVJfsfyLqTwg74DPjCFhCG7T9hvC10Obl5AzAaq9ZDVa7bXIEXvehcaO1MW9ur817Bhh4tVLxVpdeBqalqnk35l815SGbLVzYqVHDQP-i_3fGO3tRUaJ0YkhiWa_uBmCADi1ktyDAQ5zaH7NNl_Pl9ZYIC60I_e9Wis9115BpOU1Ge19L8O4fderyiF7nMt_nf6iAbczT1WGLkaLvSTMuE-h4YJ7Qxb4esTlC_Pg0npvWPXdKDxMhtrywXRkorneogzK748jkwM3-NO5MLTR4lXB8yoxv_m0D30aAPq02PxPE1dD0Ab0WtD3unLtMILFLd9c_9MVt_AYNv6aG3zMBKl9qO0jSSVjyf1QTehsytNo2Ob6Nb1qfBrw1B76CWLO-iGwObtXEPfVzyFAM9cJ2nWPEUG55iy1M8LLHmKXY8xY6nP799n2HL0FfY8RNrft5HJ7s7x_19zzb48DISk7kXKbG9IqY0UJZimDHpp5mMRCEpjbOcxmGYSxHDClwkqSwikuRJDv5wnoQSXN0gfIA2ynEpNxGWNI_StEepLFISKBGiLPVFEZIojHJGSBt1lneUZ1b9XjVhGXGThRFyDQU3ULTRS3f0xKi-_OG450twOEzL6l2bKOW4mvEe2HxgnTOftdFDA5Y70xLlNoobMLoDlOR785tyeKal3y3R2uiDAbz5E-2wc6sSdsZHFZ9JPqmF_7kQksK97PGAxBTOJmLO_IzwRPklhOm0h0dXvqzH6OblE_8EbcynlXwKNvs8faafiF8esvAp
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baseline+and+longitudinal+grey+matter+changes+in+newly+diagnosed+Parkinson%E2%80%99s+disease%3A+ICICLE-PD+study&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Mak%2C+Elijah&rft.au=Su%2C+Li&rft.au=Williams%2C+Guy+B.&rft.au=Firbank%2C+Michael+J.&rft.date=2015-10-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=138&rft.issue=10&rft.spage=2974&rft.epage=2986&rft_id=info:doi/10.1093%2Fbrain%2Fawv211&rft_id=info%3Apmid%2F26173861&rft.externalDocID=PMC4671477
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon